Page last updated: 2024-10-19

niacinamide and Thrombopenia

niacinamide has been researched along with Thrombopenia in 12 studies

nicotinamide : A pyridinecarboxamide that is pyridine in which the hydrogen at position 3 is replaced by a carboxamide group.

Research Excerpts

ExcerptRelevanceReference
"In our patients, nicotinamide effectively decreased phosphorus, increased high-density lipoprotein, and caused thrombocytopenia."9.15Oral nicotinamide reduces serum phosphorus, increases HDL, and induces thrombocytopenia in hemodialysis patients: a double-blind randomized clinical trial. ( Abbaspour, MR; Belladi Musavi, SS; Ghorbani, A; Hayati, F; Lashkarara, GR; Shahbazian, H; Zafar Mohtashami, A, 2011)
"To observe the efficacy and side effects of transarterial chemoembolization (TACE) combined with sorafenib for advanced hepatocellular carcinoma (HCC)."9.14[Clinical observation of transarterial chemoembolization combined with sorafenib for advanced hepatocellular carcinoma]. ( Chen, H; Chen, Z; Lin, JH; Liu, LM; Meng, ZQ; Xu, LT; Zhou, ZH, 2010)
"Sorafenib was recently approved for the treatment of these patients."5.42Partial response to sorafenib treatment associated with transient grade 3 thrombocytopenia in a patient with locally advanced thyroid cancer. ( Abelleira, E; Cross, G; Jerkovich, F; Pitoia, F; Urciuoli, C, 2015)
"In our patients, nicotinamide effectively decreased phosphorus, increased high-density lipoprotein, and caused thrombocytopenia."5.15Oral nicotinamide reduces serum phosphorus, increases HDL, and induces thrombocytopenia in hemodialysis patients: a double-blind randomized clinical trial. ( Abbaspour, MR; Belladi Musavi, SS; Ghorbani, A; Hayati, F; Lashkarara, GR; Shahbazian, H; Zafar Mohtashami, A, 2011)
"To observe the efficacy and side effects of transarterial chemoembolization (TACE) combined with sorafenib for advanced hepatocellular carcinoma (HCC)."5.14[Clinical observation of transarterial chemoembolization combined with sorafenib for advanced hepatocellular carcinoma]. ( Chen, H; Chen, Z; Lin, JH; Liu, LM; Meng, ZQ; Xu, LT; Zhou, ZH, 2010)
" However, niacin can cause flushing and niacinamide probably cause thrombocytopenia."4.90Benefits and harm of niacin and its analog for renal dialysis patients: a systematic review and meta-analysis. ( Feng, L; He, YM; Huo, DM; Liao, YH; Yang, ZH, 2014)
"Hepatocellular carcinoma (HCC) is increasing in numbers worldwide, and no effective systemic treatment existed for advanced HCC until SHARP (Sorafenib in HCC Assessment Randomized Protocol) study proved sorafenib (Nexavar((R)), Bayer Pharmaceuticals, Wayne, NJ, USA) prolonged survival versus placebo."3.76Platelet count less than SHARP: what does a case series reveal? ( Saif, MW, 2010)
" No significant drug-drug interactions were observed."2.90A phase I study of the HDM2 antagonist SAR405838 combined with the MEK inhibitor pimasertib in patients with advanced solid tumours. ( de Jonge, M; de Weger, VA; Demers, B; Deutsch, E; Goodstal, S; Hsu, K; Langenberg, MHG; Lolkema, M; Macé, S; Schellens, JHM; Thomas, K; Tuffal, G; Varga, A, 2019)
" Common adverse events (AEs) were also studied."2.52Efficacy and safety of angiogenesis inhibitors in advanced non-small cell lung cancer: a systematic review and meta-analysis. ( Chen, Y; Hong, S; Luo, S; Tan, M; Wang, S; Zhang, L, 2015)
"Sorafenib was recently approved for the treatment of these patients."1.42Partial response to sorafenib treatment associated with transient grade 3 thrombocytopenia in a patient with locally advanced thyroid cancer. ( Abelleira, E; Cross, G; Jerkovich, F; Pitoia, F; Urciuoli, C, 2015)
" Their baseline characteristics, radiologic response, adverse events, and survival status were assessed."1.38Efficacy and safety of vascular endothelial growth factor receptor tyrosine kinase inhibitors in patients with metastatic renal cell carcinoma and poor risk features. ( Ahn, H; Ahn, JH; Ahn, S; Ahn, Y; Hong, JH; Kim, CS; Kim, TW; Lee, JL; Park, I; Park, K; Park, S; Song, C, 2012)
"Temsirolimus appears to be an effective and well-tolerated substance in the treatment of patients with a good performance status, low MSKCC score and stable disease under previous antiangiogenic treatment in advanced renal cell cancer."1.37Efficacy of temsirolimus after previous treatment with sunitinib, sorafenib or everolimus in advanced renal cell cancer. ( Greil, R; Grundbichler, M; Kappacher, A; Mlineritsch, B; Moik, M; Ressler, S; Rosenlechner, S, 2011)

Research

Studies (12)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (8.33)29.6817
2010's11 (91.67)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Cai, W1
Yuan, YC1
Li, MY1
Kong, W1
Dong, BJ1
Chen, YH1
Zhang, J1
Xue, W1
Huang, YR1
Zhou, LX1
Huang, JW1
de Weger, VA1
de Jonge, M1
Langenberg, MHG1
Schellens, JHM1
Lolkema, M1
Varga, A1
Demers, B1
Thomas, K1
Hsu, K1
Tuffal, G1
Goodstal, S1
Macé, S1
Deutsch, E1
He, YM1
Feng, L1
Huo, DM1
Yang, ZH1
Liao, YH1
Hong, S1
Tan, M1
Wang, S1
Luo, S1
Chen, Y1
Zhang, L1
Pitoia, F1
Abelleira, E1
Jerkovich, F1
Urciuoli, C1
Cross, G1
Saif, MW1
Panuganti, S1
Papoutsakis, ET1
Miller, WM1
Xu, LT1
Chen, Z1
Lin, JH1
Zhou, ZH1
Chen, H1
Meng, ZQ1
Liu, LM1
Shahbazian, H1
Zafar Mohtashami, A1
Ghorbani, A1
Abbaspour, MR1
Belladi Musavi, SS1
Hayati, F1
Lashkarara, GR1
Grundbichler, M1
Mlineritsch, B1
Ressler, S1
Moik, M1
Kappacher, A1
Rosenlechner, S1
Greil, R1
Lee, JL1
Park, I1
Park, K1
Park, S1
Ahn, Y1
Ahn, JH1
Kim, TW1
Ahn, S1
Song, C1
Hong, JH1
Kim, CS1
Ahn, H1
Rottembourg, JB1
Launay-Vacher, V1
Massard, J1

Clinical Trials (1)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
A Phase 1 Study of Combination Therapy With SAR405838 and Pimasertib in Patients With Advanced Cancer[NCT01985191]Phase 126 participants (Actual)Interventional2013-11-30Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Reviews

2 reviews available for niacinamide and Thrombopenia

ArticleYear
Benefits and harm of niacin and its analog for renal dialysis patients: a systematic review and meta-analysis.
    International urology and nephrology, 2014, Volume: 46, Issue:2

    Topics: Flushing; Humans; Lipoproteins, HDL; Niacin; Niacinamide; Phosphorus; Randomized Controlled Trials a

2014
Efficacy and safety of angiogenesis inhibitors in advanced non-small cell lung cancer: a systematic review and meta-analysis.
    Journal of cancer research and clinical oncology, 2015, Volume: 141, Issue:5

    Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic A

2015

Trials

3 trials available for niacinamide and Thrombopenia

ArticleYear
A phase I study of the HDM2 antagonist SAR405838 combined with the MEK inhibitor pimasertib in patients with advanced solid tumours.
    British journal of cancer, 2019, Volume: 120, Issue:3

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dose-Response Relationship, Drug; Femal

2019
[Clinical observation of transarterial chemoembolization combined with sorafenib for advanced hepatocellular carcinoma].
    Zhonghua zhong liu za zhi [Chinese journal of oncology], 2010, Volume: 32, Issue:9

    Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Chemoe

2010
Oral nicotinamide reduces serum phosphorus, increases HDL, and induces thrombocytopenia in hemodialysis patients: a double-blind randomized clinical trial.
    Nefrologia : publicacion oficial de la Sociedad Espanola Nefrologia, 2011, Volume: 31, Issue:1

    Topics: Administration, Oral; Adult; Aged; Diarrhea; Double-Blind Method; Female; Humans; Hyperglycemia; Hyp

2011

Other Studies

7 other studies available for niacinamide and Thrombopenia

ArticleYear
[Comparison of efficacy between sorafenib and sunitinib as first-line therapy for metastatic renal cell carcinoma and analyze prognostic factors for survival].
    Zhonghua zhong liu za zhi [Chinese journal of oncology], 2018, May-23, Volume: 40, Issue:5

    Topics: Antineoplastic Agents; Carcinoma, Renal Cell; Diarrhea; Disease Progression; Disease-Free Survival;

2018
Partial response to sorafenib treatment associated with transient grade 3 thrombocytopenia in a patient with locally advanced thyroid cancer.
    Archives of endocrinology and metabolism, 2015, Volume: 59, Issue:4

    Topics: Aged; Antineoplastic Agents; Female; Humans; Neoplasm Recurrence, Local; Neoplasm Staging; Niacinami

2015
Platelet count less than SHARP: what does a case series reveal?
    Expert opinion on drug safety, 2010, Volume: 9, Issue:1

    Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Humans; Liver Cirrhosis; Liver

2010
Bone marrow niche-inspired, multiphase expansion of megakaryocytic progenitors with high polyploidization potential.
    Cytotherapy, 2010, Volume: 12, Issue:6

    Topics: Antigens, CD34; Blood Platelets; Bone Marrow; Cell Culture Techniques; Cell Differentiation; Cell Li

2010
Efficacy of temsirolimus after previous treatment with sunitinib, sorafenib or everolimus in advanced renal cell cancer.
    Oncology, 2011, Volume: 80, Issue:1-2

    Topics: Aged; Aged, 80 and over; Anemia; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Proto

2011
Efficacy and safety of vascular endothelial growth factor receptor tyrosine kinase inhibitors in patients with metastatic renal cell carcinoma and poor risk features.
    Journal of cancer research and clinical oncology, 2012, Volume: 138, Issue:4

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Benzenes

2012
Thrombocytopenia induced by nicotinamide in hemodialysis patients.
    Kidney international, 2005, Volume: 68, Issue:6

    Topics: Humans; Kidney Failure, Chronic; Niacinamide; Phosphorus; Renal Dialysis; Thrombocytopenia; Vitamin

2005